Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
Go back to Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting| (NASDAQ: KYMR) | Delayed: 110.34 -3.03 (2.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $113.37 | 52 Week High | $ | |||
| Open | $110.92 | 52 Week Low | $ | |||
| Day High | $113.63 | P/E | N/A | |||
| Day Low | $110.18 | EPS | $ | |||
| Volume | 538,338 | |||||
